Summary
It has been suggested, based on animal experiments and limited human data, that the antihypertensive drug hydralazine might be carcinogenic, and among the sites of concern are the lung and colon.
To assess the possible relationship between the use of hydralazine and lung and colorectal cancers in humans, we compared 1006 cases of lung cancer with 3531 hospital control subjects, and 972 cases of colorectal cancer with 3276 controls. Data were collected by interview in hospitals in the United States and Canada.
Overall, 1.1% of the lung cancer cases, 1.6% of the colorectal cancer cases, and 1.5% of the controls had used hydralazine. Compared with those who had never used hydralazine, the relative risk estimate of lung cancer for those who first took the drug at least 18 months before hospital admission was 1.1 (95% confidence interval 0.4–2.9). The estimate for use for at least 1 year was 1.4 (0.5–3.8) and for use for at least 5 years the estimate was 0.9 (0.2–4.3). The corresponding relative risk estimates for colorectal cancer were 1.2 (0.5–2.5) for any use, 1.7 (0.8–3.7) for use for at least one year, and 2.4 (0.8–6.9) for five or more years of use. Other antihypertensive treatments and risk factors, including cigarette smoking in the analysis of lung cancer, were taken into account in these estimates.
Although the effect of use after long latent intervals could not be evaluated, the results provide no support for the hypothesis that hydralazine use increases the risk of lung cancer. There is also no evidence that hydralazine increases the risk of colorectal cancer, but an effect after extended durations of use cannot be ruled out.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
International Agency for Research in Cancer (1980) Some pharmaceutical drugs. IARC Monogr Eval Carcinog Risk Chem Hum 24: 85–100
Timbrell JA, Harland SJ (1979) Identification and quantification of hydrazine in the urine of patients treated with hydralazine. Clin Pharmacol Ther 26: 81–88
Blair IA, Mansilla Tinoco R, Brodie MJ, Clare RA, Doltery CT, Timbrell JA, Beever IA (1985) Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. Hum Toxicol 4: 195–202
International Agency for Research in Cancer (1974) Some aromatic amines, hydrazine and related substances, N-nitroso compounds and miscellaneous alkylating agents. IARC Monogr Eval Carcinog Risk Chem Man 4: 127–136
Balo J (1979) Role of hydrazine in carcinogenesis. Adv Cancer Res 30: 151–164
Perry HM (1963) Carcinoma and hydralazine toxicity in patients with malignant hypertension. J Am Med Assoc 186: 1020–1022
Anonymous (1963) Malignant hypertension, hydralazine toxicity, and carcinoma. J Am Med Assoc 186: 1014
Williams RR, Feinleib M, Conner RJ, Stegens NL (1978) Case-control study of antihypertensive and diuretic use by women with malignant and benign breast lesions detected in a mammography screening program. J Nat Cancer Inst 61: 327–335
Friedman GD, Ury HK (1983) Screening for possible drug carcinogenicity: Second report of findings. J Nat Cancer Inst 71: 1165–1175
Kaufman DW, Kelly JP, Rosenberg L. Stolley PD, Schottenfeld D, Shapiro S (1987) Hydralazine and breast cancer. J Nat Cancer Inst 78: 243–246
Mantel H, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies. J Nat Cancer Inst 22: 719–748
Miettinen OS (1976) Estimability and estimation in case-referent studies. Am J Epidemiol 103: 226–235
Armitage P (1971) Statistical methods in medical research. Wiley, New York, 380–384
Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KT, Ashley RL, Beagrie M, Ryan JA, Corey L (1987) Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 317: 973–977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaufman, D.W., Kelly, J.P., Rosenberg, L. et al. Hydralazine use in relation to cancers of the lung, colon, and rectum. Eur J Clin Pharmacol 36, 259–264 (1989). https://doi.org/10.1007/BF00558157
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558157